Company news
Nuvectis Pharma, Inc. news in 2023
Nuvectis Pharma, Inc.'s news releases, calls and decks from 2023, newest first.
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
December 17, 2023
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
November 7, 2023
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
October 23, 2023
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
September 24, 2023
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
September 20, 2023
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
September 11, 2023
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
September 5, 2023
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
August 16, 2023
Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights
August 8, 2023
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
June 19, 2023
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
May 14, 2023
Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights
May 9, 2023
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
April 17, 2023
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
April 9, 2023
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
March 16, 2023
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
March 9, 2023
Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights
March 6, 2023
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
February 22, 2023
Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to Enzalutamide, the Active Ingredient in Xtandi®
February 8, 2023
Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
January 3, 2023
Decks in 2023
- Investor Presentation (April 2023)
Investor deck · 23 slides · April 2023